UBS Group
ANAC

UBS Group’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

UBS Group’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-155,000
Closed -$17.5M – 8938
2015
Q4 		$17.5M Buy
+155,000
New +$17.1M 0.01% 1034

Other funds holding ANAC

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

UBS Group's ANAC Position: Q2 2016 in Review

UBS Group sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 84,057 shares — an estimated $4.49M sold.

UBS Group first reported a position in ANAC in Q4 2014 and held it in 6 quarters. The position peaked at $13.8M in Q3 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

  • UBS Group reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • UBS Group sold 84,057 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $4.49M.
  • UBS Group first reported a position in ANACOR PHARMACEUTICALS INC COM in Q4 2014 and held it in 6 quarters.
  • UBS Group's ANACOR PHARMACEUTICALS INC COM position peaked at $13.8M in Q3 2015.
  • 2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on UBS Group's 13F filing for Q2 2016, filed 12 Aug 2016.